TY  - BOOK
AU  - Schreiber, Matthew P
AU  - Shorr, Andrew F
TI  - Inhaled antibiotics for the treatment of pneumonia. [Review]
SN  - 1070-5287
PY  - 2019///
KW  - *Amikacin/ad [Administration & Dosage]
KW  - *Anti-Bacterial Agents/ad [Administration & Dosage]
KW  - *Pneumonia, Bacterial/dt [Drug Therapy]
KW  - *Pneumonia, Ventilator-Associated/dt [Drug Therapy]
KW  - Administration, Inhalation
KW  - Humans
KW  - MedStar Washington Hospital Center
KW  - Medicine/Pulmonary-Critical Care
KW  - Journal Article
N1  - Available online from MWHC library: 1999 - present
N2  - PURPOSE OF REVIEW: To describe recent developments in trials exploring inhaled antibiotics for treating severe pneumonia; RECENT FINDINGS: Three recent randomized studies investigated the potential role for aerosolized antibiotics for gram-negative pneumonia in ventilated patients. One single center, nonblinded investigation suggested a benefit with inhaled amikacin for resistant gram-negative infections. However, two multicenter, blinded trials found no benefit to adjunctive nebulized amikacin for severe gram-negative pneumonia; SUMMARY: Well done clinical trials do not support the routine use of inhaled amikacin for pneumonia in ventilated patients. There may be a potential role for aerosolized antibiotics when other options are limited
UR  - https://dx.doi.org/10.1097/MCP.0000000000000557
ER  -